Takeda Pharmaceutical Company has entered a global strategic partnership with China’s Innovent Biologics to acquire rights to two late-stage investigational oncology medicines and an option on an early-stage program, the companies announced October 22. Under the agreement, Takeda will pay
“The complexity is there’s an antibody component, linker-payloads with highly potent toxic agents that need high containment, and linking a biologic with a highly potent small molecule – it’s inherently challenging.” Dr. Harch Ooi, VP of Manufacturing and Chemistry at
“Outsourcing is about giving the things you don’t excel at to someone who does them exceptionally well. That’s what speeds development and delivery,” says Kindeva’s CEO, Milton Boyer. Milton brings nearly 30 years of pharmaceutical manufacturing experience as a contract
Merck and AstraZeneca’s decisions reflect a broader industry exodus as drugmakers cite government undervaluation, lack of competitive environment and prioritise US investment. The UK’s pharmaceutical sector crisis has dramatically deepened this week, with AstraZeneca pausing its entire £650m UK investment
“CMC success is rarely the product of last-minute fixes. It comes from embedding strategic foresight, regulatory awareness, and cross-functional collaboration from day one.” — Evelien Stalmeijer Evelien Stalmeijer, Chief Cell & Gene Therapy Consultant at eXmoor Pharma, brings deep expertise
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
